Bi-specific fusion proteins

US10407512B2 · kind B2 · utility

Assignee

• Silver Creek Pharmaceuticals, Inc. · US

Inventors

• Ulrik Nielsen · Quincy, US
• Thomas Wickham · Groton, US
• Birgit Schoeberl · Cambridge, US
• Brian Harms · Brookline, US
• Bryan Linggi · Richland, US
• Matthew Onsum · Corona, US
• Byron DeLaBarre · Arlington, US
• Shaun M. Lippow · Somerville, US

Key dates

• Filing date: Jun 9, 2017
• Grant date: Sep 10, 2019
• Expiry date: Jun 9, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/80
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.